OBJECTIVES: To investigate the frequency of anti-infliximab antibodies in patients with RA and the associations with adverse drug reactions and treatment failure. METHODS: Based on the DANBIO registry, patients with RA who initiated treatment with infliximab at Hvidovre Hospital between 2000 and 2008 and had available serum samples were identified. The patients were followed for 52 weeks. Anti-infliximab antibodies were determined prior to infusion at baseline and during follow-up (weeks 2, 6, 14 and 52 or at withdrawal) using the IMPACT indirect assay (Roche Diagnostics) and merged with clinical data prospectively registered in the DANBIO registry. RESULTS: A total of 218 patients with RA were included (80% females, median age 56 years, disease duration 10 years, 65% RF positive, median DAS28 = 5.0). During the 52-week follow-up, 28 patients (13%) withdrew due to adverse events and 50 (23%) due to treatment failure. Antibodies were detected in 118 patients (54%) during follow-up. Patients with detectable anti-infliximab antibodies after 6 weeks had an increased risk of adverse drug reactions [hazard ratio (HR) = 5.06, 95% CI 2.36, 10.84; P < 0.0001] compared with patients without anti-infliximab antibodies. Similar results were observed in patients with anti-infliximab antibodies after 14 weeks (HR = 3.30, 95% CI 1.56, 6.99; P = 0.0009). Patients with detectable anti-infliximab antibodies during the 52-week follow-up were less likely to achieve sustained minimal disease activity and remission. CONCLUSION: Early anti-infliximab antibody formation increased the risk of adverse drug reactions, including infusion reactions. Anti-infliximab antibody formation during the 52-week follow-up decreased the likelihood of minimal disease activity and remission in patients with RA treated in routine care.
OBJECTIVES: To investigate the frequency of anti-infliximab antibodies in patients with RA and the associations with adverse drug reactions and treatment failure. METHODS: Based on the DANBIO registry, patients with RA who initiated treatment with infliximab at Hvidovre Hospital between 2000 and 2008 and had available serum samples were identified. The patients were followed for 52 weeks. Anti-infliximab antibodies were determined prior to infusion at baseline and during follow-up (weeks 2, 6, 14 and 52 or at withdrawal) using the IMPACT indirect assay (Roche Diagnostics) and merged with clinical data prospectively registered in the DANBIO registry. RESULTS: A total of 218 patients with RA were included (80% females, median age 56 years, disease duration 10 years, 65% RF positive, median DAS28 = 5.0). During the 52-week follow-up, 28 patients (13%) withdrew due to adverse events and 50 (23%) due to treatment failure. Antibodies were detected in 118 patients (54%) during follow-up. Patients with detectable anti-infliximab antibodies after 6 weeks had an increased risk of adverse drug reactions [hazard ratio (HR) = 5.06, 95% CI 2.36, 10.84; P < 0.0001] compared with patients without anti-infliximab antibodies. Similar results were observed in patients with anti-infliximab antibodies after 14 weeks (HR = 3.30, 95% CI 1.56, 6.99; P = 0.0009). Patients with detectable anti-infliximab antibodies during the 52-week follow-up were less likely to achieve sustained minimal disease activity and remission. CONCLUSION: Early anti-infliximab antibody formation increased the risk of adverse drug reactions, including infusion reactions. Anti-infliximab antibody formation during the 52-week follow-up decreased the likelihood of minimal disease activity and remission in patients with RA treated in routine care.
Entities:
Keywords:
DANBIO registry; adverse drug reactions; anti-TNF therapy; drug response; infliximab; neutralizing antibodies; pharmacological biomarkers; rheumatoid arthritis; treatment failure
Authors: E M H Schmitz; S Benoy-De Keuster; A J L Meier; V Scharnhorst; R A M Traksel; M A C Broeren; L J J Derijks Journal: Clin Rheumatol Date: 2017-06-07 Impact factor: 2.980
Authors: Ariana Montes; Eva Perez-Pampin; Federico Navarro-Sarabia; Virginia Moreira; Arturo Rodríguez de la Serna; Berta Magallares; Yiannis Vasilopoulos; Theologia Sarafidou; Antonio Fernández-Nebro; María Del Carmen Ordóñez; Javier Narváez; Juan D Cañete; Ana Marquez; Dora Pascual-Salcedo; Beatriz Joven; Patricia Carreira; Manuel J Moreno-Ramos; Rafael Caliz; Miguel Angel Ferrer; Rosa Garcia-Portales; Francisco J Blanco; Cesar Magro; Enrique Raya; Lara Valor; Juan J Alegre-Sancho; Alejandro Balsa; Javier Martin; Darren Plant; John Isaacs; Ann W Morgan; Anne Barton; Anthony G Wilson; Juan J Gómez-Reino; Antonio Gonzalez Journal: Arthritis Res Ther Date: 2015-03-18 Impact factor: 5.156
Authors: Ignacio Ortea; Bernd Roschitzki; Rosario López-Rodríguez; Eva G Tomero; Juan G Ovalles; Javier López-Longo; Inmaculada de la Torre; Isidoro González-Alvaro; Juan J Gómez-Reino; Antonio González Journal: PLoS One Date: 2016-04-06 Impact factor: 3.240